First European approvals for Boehringer's olodaterol

Boehringer Ingelheim GmbH (Ingelheim, Germany) said the U.K., Denmark and Iceland approved Striverdi Respimat olodaterol as maintenance treatment for chronic obstructive pulmonary disease (COPD). The MAA was approved under the EU's decentralized procedure, with the Netherlands acting as the reference member state. Boehringer submitted the MAA in May. The long-acting beta 2 agonist (LABA) is already approved in Canada and Russia. ...